Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2009

View Archived Issues

Genentech and Array BioPharma report novel Akt-1 protein kinase inhibitors

Oligomer-guanidine conjugates active against pain claimed by Nektar Therapeutics

GABA-A alpha5 receptor ligands for cognitive disorders presented by Roche

Simvastatin not beneficial in aneurysmal subarachnoid hemorrhage

Apixaban thromboprophylaxis and bleeding risk compared to those of enoxaparin

Biotie Therapies describes active metabolite of anti-inflammatory agent ELB-353

BMS reports development of its PPARalpha-selective dual agonist BMS-759509

Neurotune obtains approval for phase II dimiracetam trial in neuropathic pain

Advaxis to collaborate with City of Hope for leukemia and lymphoma vaccine

ActoGeniX receives grant to develop AG-013 for treatment of oral mucositis

FDA grants accelerated approval of Hiberix vaccine for Hib booster dose

11beta-HSD1 inhibitors for metabolic syndrome reported by Wyeth

Pfizer tests mGluR2 positive allosteric modulators in psychosis models

Glenmark discloses novel VR1 antagonists for the treatment of pain

Biovitrum AB reports the invention of 11beta-HSD1 inhibitors for glaucoma

Novel c-Met inhibitors designed at sanofi-aventis

Aska Pharmaceuticals describes novel PPAR activators

NIH develops novel PDE4 inhibitors for respiratory disorders

Quest launches influenza A H1N1 test in the U.S.

New indication for Helixate FS approved by FDA

Bristol-Myers Squibb reports second quarter 2009 results

Health Canada grants approval to Anika's Monovisc for osteoarthritis of the knee

Cel-Sci expands flu virus research program

The Medicines Company withdraws European MAA for oritavancin in cSSSI

Phase II trial of NeoFuse in lumbar spinal fusion surgery cleared by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...